A Hong Kong man on trial for allegedly murdering his live-in girlfriend four years ago has said he thought she was an alien because she did not bear his child. A High Court jury of four men and three women heard on Thursday that Tang Lung-fai, 56, admitted causing the death of Fok Sin-yee, 38, during a scuffle at their home in Mui Tsz Lam village, Ma On Shan, on or about April 14, 2022. But the de...
A Hong Kong man on trial for allegedly murdering his live-in girlfriend four years ago has said he thought she was an alien because she did not bear his child. A High Court jury of four men and three women heard on Thursday that Tang Lung-fai, 56, admitted causing the death of Fok Sin-yee, 38, during a scuffle at their home in Mui Tsz Lam village, Ma On Shan, on or about April 14, 2022. But the defendant, who ran a private campsite near his home, denied intending to kill his partner or cause her grievous bodily harm during their quarrel over whether she was human. Advertisement In his opening address, senior assistant director of public prosecutions Raymond Cheng Hoi-chung said the couple met in a bar around 2012 and began living together at the single-storey house three years later. Cheng said an argument on the evening of April 13 that year escalated into a fight the next morning, during which Tang inflicted serious injuries on the deceased. Advertisement The defendant made three emergency calls between 6.13am and 6.30am on April 14, saying he had killed his girlfriend and urging police to attend the scene.
Key Points On March 7, big changes are coming to Social Security. The changes could affect access to services and how seniors claim benefits. The Trump administration's Social Security policy is the reason for the change. The $23,760 Social Security bonus most retirees completely overlook › Retirees who are collecting Social Security or on track to claim benefits are in for a big change on March 7...
Key Points On March 7, big changes are coming to Social Security. The changes could affect access to services and how seniors claim benefits. The Trump administration's Social Security policy is the reason for the change. The $23,760 Social Security bonus most retirees completely overlook › Retirees who are collecting Social Security or on track to claim benefits are in for a big change on March 7. With less than a week left until the change happens, seniors need to be aware of what's coming down the pipeline. Here's what's changing on March 7, along with some details about why the change is occurring. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » This major Social Security change is happening in less than a week The huge change to Social Security that's happening has to do with the implementation of: A new National Appointment Scheduling Calendar (NASC) A new National Workload Management (NWLM) platform While Social Security is a federal program, their customer service has traditionally been more of a local job. There were many field offices across the United States that helped seniors with crucial retirement planning tasks, such as claiming benefits. This is changing, though. Instead of retirees calling up or visiting their local Social Security office, scheduling will now be done nationwide. Tasks will be assigned to staff members based on their availability and skill sets, instead of geographic location. Why is this Social Security change being made, and what does it mean for seniors? The stated reason for the Social Security change is to speed up service at the local level and to better allocate resources by moving away from the local model. However, there's a lot of speculation that the change is necessary because of major staffing cuts at local Social Security offices. The reality is that...
(RTTNews) - Bioxytran, Inc. (BIXT) announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on its planned Phase 3 registrational trial. The data, released on March 2, 2026, establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval. The company has entered regulatory discu...
(RTTNews) - Bioxytran, Inc. (BIXT) announced positive dose optimization results for its lead antiviral candidate, ProLectin-M, and provided an update on its planned Phase 3 registrational trial. The data, released on March 2, 2026, establish the optimal dosing strategy and support advancement into a pivotal study intended to enable full regulatory approval. The company has entered regulatory discussions with the U.S. Food and Drug Administration (FDA) and India's Central Drugs Standard Control Organization to finalize the design of the Phase 3 trial. The study is expected to enroll approximately 408 participants in a randomized, placebo-controlled outpatient setting. The primary endpoint will measure statistically significant viral clearance or clinical improvement by Day 5 compared to placebo, targeting standard-risk patients with mild-to-moderate COVID-19 as well as other viral infections, including influenza and RSV. Dose optimization confirmed that a 16,800 mg/day regimen achieved 90% viral clearance by Day 5 while maintaining a favorable safety profile. Earlier stages had evaluated lower doses, but the March 2 data identified 16,800 mg/day as the optimal balance between antiviral activity and tolerability, providing clarity as the company advances into Phase 3 planning. ProLectin-M employs a differentiated mechanism of action through galectin antagonism, designed to block viral entry into host cells. This approach contrasts with replication inhibitors such as Pfizer's Paxlovid, which act after infection has occurred. Bioxytran believes its entry-blocking strategy may offer a potential first-line treatment option, reduce rebound risks, minimize drug-to-drug interactions, and maintain broad applicability across viral variants. Beyond COVID-19, Bioxytran is expanding its galectin antagonist platform. On February 23, 2026, the company initiated a collaboration with the University of Georgia to evaluate compound PHM23 against H5N1 avian influenza strains, part of a ...
Lari Bat/iStock via Getty Images Executive summary The Fund returned 4.54% (IS share class) during Q4 vs. 3.81% for the Russell 1000® Value Index. Over time the Fund seeks outperformance through access to two primary sources of alpha: equity income security selection and an index-based overlay. Stock selection within the equity income security sleeve contributed most to relative performance during...
Lari Bat/iStock via Getty Images Executive summary The Fund returned 4.54% (IS share class) during Q4 vs. 3.81% for the Russell 1000® Value Index. Over time the Fund seeks outperformance through access to two primary sources of alpha: equity income security selection and an index-based overlay. Stock selection within the equity income security sleeve contributed most to relative performance during the quarter. For the equity income security selection, the largest overweights are currently in financials, healthcare, and energy. Market Environment In the US, equities generally advanced during the fourth quarter. The Dow Jones Industrial Average® increased by 4.03%, while the Nasdaq 100 Index® increased by 2.47%. US fixed-income markets also posted gains. Markets proved resilient amid elevated uncertainty driven by a prolonged federal government shutdown and ongoing geopolitical tensions in the Middle East. Inflation, as measured by the headline Consumer Price Index, eased gradually from 3.0% year-over-year in September to 2.7% year-over-year in November. Labor market data, while disrupted and delayed, pointed to slowing momentum rather than a sharp deterioration. Economic growth remained firm, with third-quarter gross domestic product ('GDP') rising at a solid 4.3% annualized, supported by consumer spending and government outlays despite softer retail sales and business investment. Against this backdrop, the Federal Reserve cut rates by 25 basis points ( BPS ) early in the quarter, while maintaining a cautious tone and reaffirming a data-dependent policy stance as markets looked ahead to 2026. The S&P 500® Index increased by 2.66% for the quarter. Within the index, eight of the 11 Global Industry Classification Standard ('GICS') equity sectors finished in positive territory, led by health care and communication services. Value stocks outperformed growth stocks. Among other major equity benchmarks, the MSCI EAFE® Index, a measure of developed markets excluding the US a...
Michael H/DigitalVision via Getty Images This is my first coverage of the Carnival Corporation ( CCL ). In this article, I will discuss Carnival's business, recent developments, and why macro trends position Carnival as a dividend-yielding investment that will, in my opinion, provide returns somewhere in line with the market, while being low-risk and hard to disrupt. While it does not meet my pers...
Michael H/DigitalVision via Getty Images This is my first coverage of the Carnival Corporation ( CCL ). In this article, I will discuss Carnival's business, recent developments, and why macro trends position Carnival as a dividend-yielding investment that will, in my opinion, provide returns somewhere in line with the market, while being low-risk and hard to disrupt. While it does not meet my personal threshold for high-growth capital allocation, I am rating the stock a 'Buy' specifically for income-focused and low-volatility investors. Macroeconomic Trends To understand the sector better, and the resilience of Carnival's business, we must first look at the macro trends. According to Chart 1 made by the Cruise Lines International Association , the cruise industry has experienced growth, except for the period around the pandemic. Passenger volume reached a record high of 34.6 million in 2024, with 37.7 million expected in 2025. We can clearly see that the sector is experiencing steady, although slow, growth, disproving the fears that the pandemic would prove fatal for the industry. For an investor willing to invest in the slower-growth, low-risk companies, the cruise industry is a perfect example. Chart 1 (Cruise Lines International Association) Private Islands as a Margin Expansion Driver Carnival is aggressively expanding their proprietary island business vertical. Instead of docking a cruise ship at a third-party port, where they have to pay fees, while losing potential revenue to the local economy (bars, restaurants, retail), they can take the passengers to a fully-owned island, keeping high-margin service revenues in-house. One such island is Celebration Key , which opened in July 2025. Although management did not break down exact revenue figures or profitability metrics of Celebration Key, the margins improved, which is, in my opinion, also attributed to the success of Celebration Key. Carnival is planning to upgrade Half Moon Cay and Mahogany Bay, in a similar...
(RTTNews) - Dave Inc. (DAVE), a financial products and services provider, on Thursday said it has priced its upsized offering of $175 million of 0% convertible senior notes due 2031, increased from the previously announced $150 million. The company granted initial purchasers an option to buy up to an additional $25 million of notes. The offering is expected to close on March 9, 2026. Dave expects ...
(RTTNews) - Dave Inc. (DAVE), a financial products and services provider, on Thursday said it has priced its upsized offering of $175 million of 0% convertible senior notes due 2031, increased from the previously announced $150 million. The company granted initial purchasers an option to buy up to an additional $25 million of notes. The offering is expected to close on March 9, 2026. Dave expects net proceeds of about $168 million, or approximately $192.1 million if the option for additional notes is fully exercised. It plans to use around $15.1 million to fund capped call transactions entered into alongside the offering, about $70.5 million to repurchase roughly 334,000 shares, and the remainder for general corporate purposes, including additional share buybacks. The notes may be redeemed for cash beginning April 6, 2029, subject to certain share price conditions. They will be convertible at an initial rate of 3.5825 shares per $1,000 of notes, implying a conversion price of about $279.13 per share — a 32.5% premium to the last reported price of $210.67 on March 4, 2026. In connection with the offering, Dave entered into privately negotiated capped call transactions designed to reduce potential dilution from conversion of the notes. The cap price is initially set at $421.34 per share, representing a 100% premium to the March 4 closing price. Additionally, the company agreed to repurchase about 334,000 shares at $210.67 per share in privately negotiated transactions with note purchasers. Dave shares closed at $210.67 on Wednesday, up 0.91%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Gaotu Techedu press release ( GOTU ): Q4 GAAP EPADS of -$0.05. Non-GAAP basic and diluted net loss per ADS were both RMB0.32 in the fourth quarter of 2025. Revenue of $240.99M (+21.4% Y/Y) beats by $3.09M . Gross billings were RMB2,573.7 million, increased by 19.1% from RMB2,160.2 million in the same period of 2024. Net operating cash inflow was RMB964.8 million, increased by 23.1% from RMB783.6 m...
Gaotu Techedu press release ( GOTU ): Q4 GAAP EPADS of -$0.05. Non-GAAP basic and diluted net loss per ADS were both RMB0.32 in the fourth quarter of 2025. Revenue of $240.99M (+21.4% Y/Y) beats by $3.09M . Gross billings were RMB2,573.7 million, increased by 19.1% from RMB2,160.2 million in the same period of 2024. Net operating cash inflow was RMB964.8 million, increased by 23.1% from RMB783.6 million in the same period of 2024. Net operating cash inflow in the fourth quarter of 2025 was RMB964.8 million. Business Outlook Based on the Company's current estimates, total net revenues for the first quarter of 2026 are expected to be between RMB1,578 million and RMB1,598 million, representing an increase of 5.7% to 7.0% on a year-over-year basis. More on Gaotu Techedu Gaotu Techedu Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Gaotu Techedu Historical earnings data for Gaotu Techedu Financial information for Gaotu Techedu
designer491/iStock via Getty Images This is my seventh UroGen Pharma ( URGN ) article, following 11/2025's "UroGen: Expect Rough Patch Before Strong Recovery In 2026". Knee-Deep in Its Rough Patch, UroGen's Stock is Moving Erratically Price chart As shown by its chart below, UroGen's share price, share volume, and market cap have gyrated up and down in recent months with little net overall change:...
designer491/iStock via Getty Images This is my seventh UroGen Pharma ( URGN ) article, following 11/2025's "UroGen: Expect Rough Patch Before Strong Recovery In 2026". Knee-Deep in Its Rough Patch, UroGen's Stock is Moving Erratically Price chart As shown by its chart below, UroGen's share price, share volume, and market cap have gyrated up and down in recent months with little net overall change: Data by YCharts Shakespeare buffs might be mindful of Macbeth's famous lament as it applies to UroGen's share movements: ...a tale / Told by an idiot, full of sound and fury / signifying nothing... Double Danger Zone—JELMYTO + ZUSDURI The problem is UroGen is caught in a particularly treacherous version of the danger zone; the danger zone is that stretch between the time when a molecule is FDA approved until it proves its commercial viability. UroGen is actually suffering from a double dose of the danger zone. Its JELMYTO (mitomycin gel) in the treatment of low-grade upper tract urothelial cancer (UTUC) was FDA approved on 04/15/2020. As discussed in Rough Patch, its revenues have never lived up to initial expectations. As I read the situation, they are unlikely ever to do so; it seems inevitable that JELMYTO is in an unending danger zone UroGen's second approved molecule, its ZUSDURI, was FDA approved in 06/2025 for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Its initial Q3/2025 net product revenues were a nominal $1.8 million; Q4/2025 revenues were marginally improved at $14 million for Q4/2025. ZUSDURI Permanent J-Code UroGen bulls such as myself are looking for significant improvement in ZUSDURI net product revenues in upcoming quarters. This is the anticipated scenario underlying the bullish thesis in Rough Patch. Effective 01/2026, the Centers for Medicare and Medicaid Services' [CMS] permanent ZUSDURI J-Code will take effect . This J-Code will significantly simplify billing for ZUSDURI. As noted by CEO Barrett durin...
Earnings Call Insights: Webull Corporation (BULL) Q4 2025 Management View Anthony Michael Denier, President & Director, highlighted "strong progress and returns for our first full year as a public company," emphasizing record revenue and operating profit margin improvement. Denier stated, "We recorded revenue of $571 million, representing 46% growth from 2024, driven by record trading volumes acro...
Earnings Call Insights: Webull Corporation (BULL) Q4 2025 Management View Anthony Michael Denier, President & Director, highlighted "strong progress and returns for our first full year as a public company," emphasizing record revenue and operating profit margin improvement. Denier stated, "We recorded revenue of $571 million, representing 46% growth from 2024, driven by record trading volumes across all asset categories." Denier reported that customer assets reached $24.6 billion, an 81% increase from 2024, and described the successful integration and impact of their AI assistant, Vega: "Vega currently assists 1.2 million global users each week with 10% of weekly active users deploying the tool to answer over 10 million questions since creation." Denier noted, "Webull Premium, our subscription-based service for active traders and long-term investors, has reached 102,000 subscribers by year-end, surpassing the 100,000 target we set for ourselves," and outlined the goal to double the premium subscriber base in the coming year. Denier emphasized global expansion: "We now have more than 760,000 funded accounts outside the U.S.," and detailed new market entries and licensing progress in Europe and APAC. Denier stated, "Looking ahead to 2026... we have identified 3 main priorities for the year. First, we will sustain and grow our elite offerings for active traders... Second, we will continue growing our global business... Finally... we will be building on last year's partnership with Meritz to expand our B2B platform." H. Wang, CFO & Director, reported, "In the fourth quarter, Webull generated total revenue of $165.2 million, representing 50% year-over-year growth. This strong performance reflects continued strength across both trading and interest-related income streams." Outlook Denier stated, "Looking ahead, we aim to double our premium subscriber base in the coming year while continuing to enhance the product with additional features, making it the best value product ...